<DOC>
	<DOCNO>NCT01197911</DOCNO>
	<brief_summary>This open-label study ass effect hepatic impairment pharmacokinetics single oral dose aleglitazar subject mild moderate hepatic impairment ( Child-Pugh class A B ) match control subject normal hepatic function . Subjects receive single oral dose aleglitazar , assessment pharmacokinetics aleglitazar Days 1-5 . Anticipated duration study enrol subject approximately 6 week .</brief_summary>
	<brief_title>A Study The Effect Hepatic Impairment The Pharmacokinetics Aleglitazar</brief_title>
	<detailed_description />
	<criteria>Male female adult , 1870 year age inclusive Normal hepatic function mild moderate impair liver function ( ChildPugh class A B ) Body mass index ( BMI ) 18 40 kg/m2 inclusive Females must either surgically sterile , postmenopausal , willing use two reliable method contraception duration study start 3 month study start For subject hepatic impairment : evidence progressive liver disease within last 4 week , biliary liver cirrhosis cause hepatic impairment relate parenchymal disorder and/or disease For healthy volunteer : positive test hepatitis B C , alcohol intake 14 unit per week , history clinically significant alcohol drug abuse Acute infection current malignancy require treatment History clinically significant allergic disease drug hypersensitivity Positive test HIV1 HIV2 screen Participation clinical study investigational drug new chemical entity within 2 month prior screen Females pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>